Last reviewed · How we verify
Air/Oxygen
Oxygen therapy increases the concentration of oxygen available to body tissues, improving cellular oxygenation and metabolic function.
Oxygen therapy increases the concentration of oxygen available to body tissues, improving cellular oxygenation and metabolic function. Used for Hypoxemia and tissue hypoxia in various acute and chronic respiratory conditions, Supportive therapy in critical illness and perioperative settings.
At a glance
| Generic name | Air/Oxygen |
|---|---|
| Sponsor | Air Liquide Santé International |
| Drug class | Medical gas |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Critical Care |
| Phase | Phase 3 |
Mechanism of action
Supplemental oxygen increases the partial pressure of oxygen in the blood, enhancing oxygen delivery to tissues and organs. This is particularly beneficial in conditions characterized by hypoxemia or tissue hypoxia. Oxygen therapy supports aerobic metabolism and reduces the compensatory burden on the cardiovascular and respiratory systems.
Approved indications
- Hypoxemia and tissue hypoxia in various acute and chronic respiratory conditions
- Supportive therapy in critical illness and perioperative settings
Common side effects
- Oxygen toxicity (with prolonged high-concentration exposure)
- Drying of mucous membranes
- Absorption atelectasis
- Retinopathy of prematurity (in neonates)
Key clinical trials
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- Caracterization of the Combined Alterations in Respiration and aROUSal in Patients With Drug-resistant EpiLepsy (NA)
- Optimization of Exhaled Biomarker Collection and Analysis (NA)
- A Randomized Clinical Trial for Predictors of Successful Extubation of Pediatric Patients With or Without High Velocity Nasal Insufflation (NA)
- Use of Nitrous Oxide for Pain and Anxiety Management During Cervical Cerclage Removal- A Multicenter Randomized Controlled Study (NA)
- Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury (PHASE1, PHASE2)
- Combination Therapy to Improve SCI Recovery. (NA)
- Deep Versus Moderate Neuromuscular Blocking (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |